Description

Regeneron Pharmaceuticals’ $2.2 Billion Sanofi Revenue Record — A Pivotal Profit Catalyst!

Regeneron Pharmaceuticals reported a second quarter of 2026 marked by continued top-line and bottom-line growth alongside sustained commercial strength across its key products. Total revenues increased 17% year-over-year to $4.3 billion, while non-GAAP diluted earnings per share rose 11% to $14.29. Growth was primarily driven by strong performance in the company’s collaboration with Sanofi and core franchises including Dupixent, EYLEA HD, and Libtayo. Dupixent maintained its role as a significant growth driver, achieving $6 billion in global net sales, up 38% on a constant currency basis. The product demonstrated robust demand across all approved indications, contributing to the majority of year-over-year sales growth. Sanofi collaboration revenue reached a record $2.2 billion, with Regeneron’s share of profits rising 59%, supported by Dupixent’s momentum. EYLEA HD’s U.S.